Altering NAD+ metabolism to improve kidney outcomes after ICU admission
Official title: Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care
Run by GCS Ramsay Santé pour l'Enseignement et la Recherche · NCT07203131 · Data updated 2026-11-12
This study will see if changes in NAD+ metabolism are linked to acute kidney injury in adults admitted to intensive care who have normal kidney function on arrival.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | GCS Ramsay Santé pour l'Enseignement et la Recherche Academic / other |
| Locations | 1 site (Trappes) |
| Status | Recruiting |
| Started | March 17, 2025 |
| Main results expected | November 5, 2025 |
| Study ends | December 5, 2025 |
| Registry record updated | October 2, 2025 |
| Trial ID | NCT07203131 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 admitted to intensive care for high-risk reasons (shock, sepsis, cardiac arrest, unscheduled surgery, or cardiac surgery) who have normal kidney function on admission and can give informed consent are ideal candidates.
✕Probably not a fit
Patients with pre-existing chronic kidney disease or a kidney transplant, minors, those admitted for low-AKI-risk reasons, or patients unable to provide consent are unlikely to receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial enrolls adults admitted to an ICU for conditions with a high risk of acute renal injury and with normal renal function at admission. Investigators collect urine samples to measure NAD+–related metabolites and follow patients' renal course during their stay with a phone follow-up at day 28. The protocol excludes people with prior chronic kidney disease, kidney transplant recipients, minors, patients admitted for low-AKI-risk reasons, and those unable to consent. Results will correlate NAD+ pathway alterations with incidence, severity, and duration of acute kidney injury.
Why it matters
Potential benefit: If successful, identifying NAD+ metabolism changes could allow earlier detection of patients at high risk of AKI and point to treatments, such as vitamin B3, to prevent or reduce kidney injury.
How similar studies have gone: Prior animal and human work and a phase 2 trial in cardiac surgery patients have suggested that boosting NAD+ (for example with vitamin B3) can reduce AKI, so there is encouraging preliminary evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient, male or female aged over 18, * Patient admitted to intensive care for a reason with a high risk of ARI: shock, sepsis, cardio-circulatory arrest, post-operative unscheduled surgery, post-operative cardiac surgery, * Patient with normal renal function on admission, * Patient affiliated to or beneficiary of a social security scheme, * Patient having been informed and having given his/her free, informed and written consent Exclusion Criteria: * Minor patient, * History of chronic kidney disease, * History of kidney transplant, * Admission for a reason with a low risk of ARI (neuroresuscitation, voluntary drug intoxication with anxiolytics - antidepressants - psychotropic drugs), * Acute non-infectious respiratory failure, (scheduled surgery other than cardiac surgery) * Patient hospitalized without consent, * Patient in a period of exclusion due to another research still in progress at the time of inclusion, * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision, * Pregnant, breastfeeding or parturient woman.
Where it's running
-
Hôpital Privé de l'Ouest Parisien
Trappes, France Recruiting
Study contacts
- Study coordinator: Matthieu JAMME, Dr
- Email: mat.jamme@gmail.com
- Phone: 00336 87 64 61 12
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Project to improve understanding and treatment of kidney diseases
This study is trying to find better ways to understand and treat kidney diseases by looking closely at kidney samples and patient data to help create personalized care plans.
-
Trigonelline Monohydrate for NAD+ Metabolism in Healthy Adults
A small study in healthy adults tests whether taking trigonelline monohydrate by mouth for 4 weeks can change NAD+ levels and how the body handles the supplement, compared with NMN and placebo.
-
Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD
In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.
-
Single 3 mg Azvudine safety and blood-level test for adults with mild-to-moderate kidney decline and healthy adults
This trial gives a single 3 mg dose of Azvudine to adults with mild-to-moderate kidney function decline and to healthy adults to test how the body handles the drug and whether it is safe.
-
Examining amino acid loss in patients undergoing kidney treatment
This study looks at how much amino acid is lost in patients receiving kidney treatment in the ICU compared to those who aren't, to help improve nutrition for people with kidney problems.
-
Assessing quality of life in children with posterior urethral valves
This study looks at how being treated for posterior urethral valves affects the quality of life for boys aged 6 to 17, focusing on their kidney health and daily living.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.